Skip to content

VITAL-CKD

Validation of Indicators TrAcking loss and hyperfiLtration in Chronic Kidney Disease. - VITAL-CKD

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON57914
Enrollment
60
Registered
2025-02-04
Start date
2026-03-23
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease Chronic kidney disease

Interventions

None listed

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Chronic kidney disease groupStage 3 diagnosis: (e)GFR in the range 45-59 ml/min/1.73m2Between 18 and 70 years old> 1g proteinuria/24 hours or 100 mg/mmol creatinine on spot urine The healthy controls are matched to the CKD group, and in order for these participants to be eligible for participation, they must meet the following criteria:Age (no more than 5 years age difference) and sex matched to the CKD group.Between 18 and 70 years oldGFR > 90 ml/min/1.73m2Albuminuria < 3 mg/mmol creatinine in spot urine Kidney donor groupBetween 18 and 70 years oldNormal kidney function (which will be obvious by meeting clinical criteria to be eligible for donation)

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study:Pregnant womenWomen on their periodPresence of diabetes of any typeUncontrolled hypertensionNephrotic syndromeActive glomerular diseaseAny active infectionPresence of transurethral catheterPresence of urine deviation

Design outcomes

Primary

MeasureTime frame
To determine if the new technologies can be used to measure the turbidity and urine specific gravity.  Compare the proxies of turbidity and urine specific gravity for kidney damage with albuminuria and total protein that are measured by the clinical laboratory using their standard equipment. Investigate how the abovementioned markers develop over time in kidney function loss in kidney donor participants.

Secondary

MeasureTime frame
Compare the use of albuminuria/total proteinuria versus the GFR of the participants.

Countries

Netherlands

Contacts

Public ContactM.G. Vervloet

Radboud Universitair Medisch Centrum

secretariaat.nier@radboudumc.nl(024) 361 47 61

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Apr 17, 2026